Italia markets close in 4 hours 32 minutes
FTSE MIB
34.893,05 -505,77 (-1,43%) Dow Jones
40.003,59 +134,19 (+0,34%) Nasdaq
16.685,97 -12,33 (-0,07%) Nikkei 225
39.069,68 +282,30 (+0,73%) Petrolio
79,89 -0,17 (-0,21%) Bitcoin EUR
61.799,22 -43,79 (-0,07%)
NBIX Dec 2024 130.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 04:49PM EDT. Mercato aperto.
| Chiusura precedente | 11,53 |
| Aperto | 11,64 |
| Denaro | 7,10 |
| Lettera | 7,90 |
| Prezzo d'esercizio | 130,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 11,53 - 11,64 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 9 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.